Articles: disease.
-
Histiocytic sarcoma (HS) is a rare hematopoietic malignancy originating from the monocyte/macrophage bone marrow lineage. HS can occur in isolation or in association with other hematological neoplasms such as non-Hodgkin lymphoma (NHL), myelodysplasia, or acute leukemia. Clinically, HS can affect lymph nodes, gastrointestinal tract, skin, bone marrow, and spleen as well as the central nervous system. Most cases of HS follow an aggressive clinical course, with most patients dying of progressive disease within one year of diagnosis.
-
J Coll Physicians Surg Pak · Oct 2020
ReviewPreparing for a Pandemic: Our Plans and Lessons Learnt as a Department in a Tertiary Care Hospital.
This is a descriptive article aiming to present and analyse the steps of preparedness and troubleshooting of problems faced at operating rooms and intensive care unit during the ongoing coronavirus infectious disease 2019 (COVID-19) pandemic in Our Lady of Lourdes Hospital, a tertiary care hospital in Ireland from February 2020 to March 2020. Concerning preparation, we reviewed all aspects of our clinical and potential logistic issues and their accessible solutions in times of limited resources. ⋯ We found good communication and training as critical factors in the preparation for a pandemic. Key Words: COVID-19, Pandemic, Preparation, Challenges.
-
J Coll Physicians Surg Pak · Oct 2020
Comparison of Videothoracoscopy and Thoracotomy in Surgical Treatment of Pulmonary Hydatid Cyst Disease.
To evaluate the outcomes of videothoracoscopic and open surgeries for pulmonary hydatid cysts. ⋯ Videothoracoscopic removal of pulmonary hydatid cyst is a safe and advantageous procedure comparing to thoracotomy. There is a need for prospective studies with a larger sample size. Key Words: Hydatid cyst, Thoracoscopic surgery, Thoracotomy, VATS.
-
There were 33,269 apixaban-warfarin, 9,345 dabigatran-warfarin, and 42,156 rivaroxaban-warfarin matched pairs, with a median follow-up of 4-5 months. Compared with warfarin, apixaban was associated with lower rates of stroke/systemic embolism (hazard ratio [HR] 0.52; 95% confidence interval [95% CI], 0.43-0.62), major bleeding (HR 0.60; 95% CI, 0.55-0.66) and stroke/myocardial infarction/all-cause mortality (HR 0.70; 95%CI, 0.66-0.74); dabigatran was associated with lower rates of major bleeding (HR: 0.73; 95% CI, 0.62-0.85); dabigatran and rivaroxaban were associated with lower rates of stroke/myocardial infarction/all-cause mortality (HR 0.77; 95% CI, 0.69-0.86 and HR 0.81; 95% CI, 0.77-0.85, respectively). Rivaroxaban was associated with a lower rate of stroke/systemic embolism (HR 0.61; 95% CI, 0.53-0.71) and a higher rate of major bleeding (HR 1.10; 95%CI, 1.03-1.18) versus warfarin.
-
[This corrects the article DOI: 10.1371/journal.pmed.1003012.].